NasdaqGS:ACADBiotechs
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns
ACADIA Pharmaceuticals (ACAD) opened 2026 with Q1 revenue of $268.1 million and basic EPS of $0.02, against a backdrop of trailing twelve month revenue of $1.1 billion, basic EPS of $2.22 and net income of $375.7 million. Over recent quarters, the company has seen revenue move from $244.3 million in Q1 2025 to $268.1 million in Q1 2026, while quarterly basic EPS has ranged from $0.11 to $1.62. These results come within a period of margin expansion and earnings growth that investors now need...